
Christopher R Frei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2726386/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Drugs - Real World Outcomes, 2022, 9, 23-29.	0.7	12
2	Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System. Leukemia and Lymphoma, 2021, 62, 1664-1673.	0.6	7
3	Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. Frontiers in Cellular and Infection Microbiology, 2021, 11, 684515.	1.8	56
4	The in vitro activity of non-antibiotic drugs against S. aureus clinical strains. Journal of Global Antimicrobial Resistance, 2021, 27, 167-171.	0.9	10
5	Clinical impact of implementation of rapid diagnostic testing of blood cultures with Staphylococcus aureus on patient outcomes. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115474.	0.8	7
6	Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Drug Safety, 2020, 43, 17-22.	1.4	28
7	Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS). Drug Safety, 2020, 43, 363-369.	1.4	22
8	Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. International Journal of Medical Sciences, 2019, 16, 1018-1022.	1.1	31
9	Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). International Journal of Medical Sciences, 2019, 16, 1504-1509.	1.1	20
10	Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. Hospital Practice (1995), 2019, 47, 186-191.	0.5	3
11	<i>Clostridium difficile</i> Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System. International Journal of Medical Sciences, 2019, 16, 630-635.	1.1	60
12	Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics. Substance Abuse: Research and Treatment, 2019, 13, 117822181984420.	0.5	19
13	Antipseudomonal monotherapy or combination therapy for older adults with community-onset pneumonia and multidrug-resistant risk factors: a retrospective cohort study. American Journal of Infection Control, 2019, 47, 1053-1058.	1.1	5
14	2133. Clinical Impact of Implementation of Rapid Diagnostic Testing of Blood Cultures on Patient Outcomes. Open Forum Infectious Diseases, 2019, 6, S722-S722.	0.4	0
15	165. Comparative Effectiveness of Oral Fluoroquinolones vs. β-Lactams for the Treatment of Patients with Enterobacteriaceae Bloodstream Infections. Open Forum Infectious Diseases, 2019, 6, S107-S107.	0.4	0
16	Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting. Blood, 2019, 134, 795-795.	0.6	3
17	Derivation and Validation of a <i>Clostridium difficile</i> Infection Recurrence Prediction Rule in a National Cohort of Veterans. Pharmacotherapy, 2018, 38, 349-356.	1.2	20
18	Shift to community-onset Clostridium difficile infection in the national Veterans Health Administration, 2003-2014. American Journal of Infection Control, 2018, 46, 431-435.	1.1	19

#	Article	IF	CITATIONS
19	Association of statins with aortic, peripheral, and visceral artery aneurysm development. Vascular, 2017, 25, 372-381.	0.4	3
20	Know your medicine: A novel student-led community service learning program. Currents in Pharmacy Teaching and Learning, 2017, 9, 353-359.	0.4	3
21	Association of Statins with Diabetes Mellitus and Diabetic Complications: Role of Confounders During Follow-Up. Journal of Investigative Medicine, 2017, 65, 32-42.	0.7	10
22	Application of a Risk Score to Identify Older Adults with Communityâ€Onset Pneumonia Most Likely to Benefit From Empiric <i>Pseudomonas</i> Therapy. Pharmacotherapy, 2017, 37, 195-203.	1.2	2
23	Evaluation of Longâ€Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans. Pharmacotherapy, 2017, 37, 278-286.	1.2	5
24	High-throughput microarray for antimicrobial susceptibility testing. Biotechnology Reports (Amsterdam, Netherlands), 2017, 16, 44-47.	2.1	6
25	Emerging multidrug resistance in community-associated Staphylococcus aureus involved in skin and soft tissue infections and nasal colonization. Journal of Antimicrobial Chemotherapy, 2017, 72, 2461-2468.	1.3	32
26	Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System. Drugs, 2017, 77, 1345-1351.	4.9	10
27	National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014. PLoS ONE, 2017, 12, e0189227.	1.1	35
28	Risk factors for the development of active methicillin-resistant Staphylococcus aureus (MRSA) infection in patients colonized with MRSA at hospital admission. American Journal of Infection Control, 2016, 44, 1617-1621.	1.1	26
29	A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in Staphylococcus aureus skin and soft tissue infections. Annals of Clinical Microbiology and Antimicrobials, 2016, 15, 58.	1.7	9
30	Risk factors for methicillin-resistant <i>Staphylococcus aureus</i> skin and soft tissue infection in MRSA-colonized patients discharged from a Veterans Affairs hospital. Epidemiology and Infection, 2016, 144, 647-651.	1.0	7
31	Health care–associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes. Journal of Critical Care, 2016, 36, 265-271.	1.0	19
32	Predictors of <scp><i>P</i></scp> <i>seudomonas</i> and methicillinâ€resistant <scp><i>S</i></scp> <i>taphylococcus aureus</i> in hospitalized patients with healthcareâ€associated pneumonia. Respirology, 2016, 21, 157-163.	1.3	46
33	Predictors of community-associated <i>Staphylococcus aureus</i> , methicillin-resistant and methicillin-susceptible <i>Staphylococcus aureus</i> skin and soft tissue infections in primary-care settings. Epidemiology and Infection, 2016, 144, 3198-3204.	1.0	10
34	Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study). American Journal of Cardiology, 2016, 117, 647-655.	0.7	34
35	Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia. BMC Research Notes, 2015, 8, 450.	0.6	4
36	Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment. BMC Infectious Diseases, 2015, 15, 380.	1.3	14

Christopher R Frei

#	Article	IF	CITATIONS
37	Statin therapy and gastrointestinal hemorrhage: a retrospective cohort study with propensity score-matching. Pharmacoepidemiology and Drug Safety, 2015, 24, 849-857.	0.9	17
38	Comparative Value of Four Measures of Retention in Expert Care in Predicting Clinical Outcomes and Health Care Utilization in HIV Patients. PLoS ONE, 2015, 10, e0120953.	1.1	13
39	Comparative Whole Genome Sequencing of Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> Sequence Type 8 from Primary Care Clinics in a Texas Community. Pharmacotherapy, 2015, 35, 220-228.	1.2	14
40	The Association of Statin Use and Gonado-Sexual Function in Women: A Retrospective Cohort Analysis. Journal of Sexual Medicine, 2015, 12, 83-92.	0.3	6
41	Comparison of Frequency of Inflammatory Bowel Disease and Noninfectious Gastroenteritis Among Statin Users Versus Nonusers. American Journal of Cardiology, 2015, 115, 1396-1401.	0.7	20
42	Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults. Journal of General Internal Medicine, 2015, 30, 1599-1610.	1.3	64
43	Statins and Male Sexual Health: A Retrospective Cohort Analysis. Journal of Sexual Medicine, 2015, 12, 158-167.	0.3	17
44	National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996–2010 in the United States: a cross-sectional study. BMC Infectious Diseases, 2014, 14, 536.	1.3	11
45	How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak. Journal of the American Pharmacists Association: JAPhA, 2014, 54, 441-445.	0.7	11
46	Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. Breast Cancer Research and Treatment, 2014, 148, 571-580.	1.1	6
47	Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Medicine, 2014, 12, 96.	2.3	192
48	Empiric Weight-Based Vancomycin in Intensive Care Unit Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia. American Journal of the Medical Sciences, 2014, 348, 371-376.	0.4	3
49	The Effect of Statin Therapy on the Incidence of Infections: A Retrospective Cohort Analysis. American Journal of the Medical Sciences, 2014, 347, 211-216.	0.4	17
50	Statins and Musculoskeletal Adverse Events—Reply. JAMA Internal Medicine, 2014, 174, 303.	2.6	0
51	Association of Azithromycin With Mortality and Cardiovascular Events Among Older Patients Hospitalized With Pneumonia. JAMA - Journal of the American Medical Association, 2014, 311, 2199.	3.8	150
52	Non-invasive mechanical ventilation and mortality in elderly immunocompromised patients hospitalized with pneumonia: a retrospective cohort study. BMC Pulmonary Medicine, 2014, 14, 7.	0.8	10
53	Trends in catheter-associated urinary tract infections among a national cohort of hospitalized adults, 2001-2010. American Journal of Infection Control, 2014, 42, 17-22.	1.1	46
54	Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in geriatric patients with methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 653-657.	0.7	7

Christopher R Frei

#	Article	IF	CITATIONS
55	Association of Statins and Risk of Fractures in a Military Health System. Annals of Pharmacotherapy, 2014, 48, 1406-1414.	0.9	11
56	The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010. American Journal of Infection Control, 2014, 42, 1028-1032.	1.1	130
57	Comparison of the Risk of Psychological and Cognitive Disorders Between Persistent and Nonpersistent Statin Users. American Journal of Cardiology, 2014, 114, 1035-1039.	0.7	24
58	Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Pharmacology & Toxicology, 2013, 14, 12.	1.0	38
59	Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics. Current Fungal Infection Reports, 2013, 7, 89-95.	0.9	8
60	Association of Statin Use With Cataracts. JAMA Ophthalmology, 2013, 131, 1427.	1.4	99
61	Evaluation of Warfarin Management with International Normalized Ratio Selfâ€Testing and Online Remote Monitoring and Management Plus Lowâ€Dose Vitamin K with Genomic Considerations: A Pilot Study. Pharmacotherapy, 2013, 33, 1136-1146.	1.2	23
62	The United States' progress toward eliminating catheter-related bloodstream infections: Incidence, mortality, and hospital length of stay from 1996 to 2008. American Journal of Infection Control, 2013, 41, 118-121.	1.1	27
63	Frequency of Development of Connective Tissue Disease in Statin-Users Versus Nonusers. American Journal of Cardiology, 2013, 112, 883-888.	0.7	11
64	Statins and Musculoskeletal Conditions, Arthropathies, and Injuries. JAMA Internal Medicine, 2013, 173, 1318.	2.6	92
65	Psychologic Disorders and Statin Use: A Propensity Scoreâ€Matched Analysis. Pharmacotherapy, 2013, 33, 615-626.	1.2	32
66	Incidence of Musculoskeletal and Neoplastic Diseases in Patients on Statin Therapy: Results of a Retrospective Cohort Analysis. American Journal of the Medical Sciences, 2013, 345, 343-348.	0.4	21
67	Fenofibrate-associated nephrotoxicity: A review of current evidence. American Journal of Health-System Pharmacy, 2013, 70, 1219-1225.	0.5	58
68	Treatment Failure and Costs in Patients With Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections: A South Texas Ambulatory Research Network (STARNet) Study. Journal of the American Board of Family Medicine, 2013, 26, 508-517.	0.8	50
69	Impact of a New Method of Warfarin Management on Patient Satisfaction, Time, and Cost. Pharmacotherapy, 2013, 33, 1147-1155.	1.2	14
70	Hospitalizations for Cardiovascular Disease in African Americans and Whites with HIV/AIDS. Population Health Management, 2013, 16, 201-207.	0.8	11
71	Brief Primer on <i>Clostridium difficile</i> Infection Costs, Reimbursement, and Government Regulation. Hospital Pharmacy, 2013, 48, S14-S18.	0.4	0
72	Potential complications of Medicare reimbursement policy regarding health-care-associated infections. American Journal of Health-System Pharmacy, 2012, 69, 190-192.	0.5	3

#	Article	IF	CITATIONS
73	Population-Based Study of Statins, Angiotensin II Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors on Pneumonia-Related Outcomes. Clinical Infectious Diseases, 2012, 55, 1466-1473.	2.9	137
74	The State of Disparities in Opportunistic Infection Prophylaxis for Blacks With HIV/AIDS. Medical Care, 2012, 50, 920-927.	1.1	2
75	Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infectious Diseases, 2012, 12, 104.	1.3	26
76	Antibacterials as Adjuncts to Incision and Drainage for Adults with Purulent Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infections. Drugs, 2012, 72, 339-351.	4.9	11
77	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. Journal of Clinical Lipidology, 2012, 6, 19-26.	0.6	20
78	Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. American Journal of Health-System Pharmacy, 2012, 69, 1863-1870.	0.5	18
79	Antimicrobial-Impregnated Discs for Prevention of Intravenous Catheter-Related Infections. American Journal of Infectious Diseases, 2012, 8, 50-59.	0.1	3
80	Cardiovascular Disease in Blacks with HIV/AIDS in the United States: A Systematic Review of the Literature. Open AIDS Journal, 2012, 6, 29-35.	0.1	7
81	Fluoroquinolones in Community-Acquired Pneumonia. Drugs, 2011, 71, 757-770.	4.9	14
82	Health Care-associated Pneumonia: An Evidence-based Review. American Journal of Medicine, 2011, 124, 689-697.	0.6	31
83	The Environmental and Social Influences of HIV/AIDS in Sub-Saharan Africa: A Focus on Rural Communities. International Journal of Environmental Research and Public Health, 2011, 8, 2967-2979.	1.2	30
84	A clinical pathway for community-acquired pneumonia: an observational cohort study. BMC Infectious Diseases, 2011, 11, 188.	1.3	12
85	Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study. BMC Women's Health, 2011, 11, 27.	0.8	13
86	Response: Re: Trimethoprim-sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections. Journal of the American Board of Family Medicine, 2011, 24, 332-333.	0.8	1
87	Once-Daily Amikacin Dosing in Burn Patients Treated with Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2011, 55, 4639-4642.	1.4	24
88	Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. American Journal of Health-System Pharmacy, 2011, 68, 347-352.	0.5	35
89	Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. European Respiratory Journal, 2011, 38, 878-887.	3.1	103
90	Prevalence, Severity, and Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Skin and Soft Tissue Infections in 10 Medical Clinics in Texas: A South Texas Ambulatory Research Network (STARNet) Study. Journal of the American Board of Family Medicine, 2011, 24, 543-550.	0.8	37

#	Article	IF	CITATIONS
91	Differences in National Antiretroviral Prescribing Patterns Between Black and White Patients with HIV/AIDS, 1996–2006. Southern Medical Journal, 2011, 104, 794-800.	0.3	11
92	Disparities of Care for African-Americans and Caucasians with Community-Acquired Pneumonia: A Retrospective Cohort Study. BMC Health Services Research, 2010, 10, 143.	0.9	28
93	Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clinical Therapeutics, 2010, 32, 293-299.	1.1	78
94	Retrospective cohort study of hospitalized adults treated with vancomycin or clindamycin for methicillin-resistant Staphylococcus aureus skin infections. Clinical Therapeutics, 2010, 32, 2024-2029.	1.1	5
95	Trimethoprim-Sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections. Journal of the American Board of Family Medicine, 2010, 23, 714-719.	0.8	49
96	Influenza vaccination rates among pharmacists. Journal of the American Pharmacists Association: JAPhA, 2010, 50, 517-522.	0.7	11
97	Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. Journal of Pediatric Surgery, 2010, 45, 1967-1974.	0.8	66
98	Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia. American Journal of Medicine, 2010, 123, S39-S46.	0.6	9
99	Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based s Current Medical Research and Opinion, 2009, 25, 859-868.	st od y.	13
100	Continuous versus Intermittent Infusion of Oxacillin for Treatment of Infective Endocarditis Caused by Methicillin-Susceptible <i>Staphylococcus aureus</i> . Antimicrobial Agents and Chemotherapy, 2009, 53, 2014-2019.	1.4	44
101	Disparities in Antiretroviral Prescribing for Blacks and Whites in the United States. Journal of the National Medical Association, 2009, 101, 1140-1148.	0.6	6
102	Black race as a predictor of poor health outcomes among a national cohort of HIV/AIDS patients admitted to US hospitals: a cohort study. BMC Infectious Diseases, 2009, 9, 127.	1.3	20
103	Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in highâ€risk liver transplant recipients. Transplant Infectious Disease, 2009, 11, 106-111.	0.7	17
104	Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leukemia and Lymphoma, 2009, 50, 1442-1447.	0.6	41
105	Evaluating HIV/AIDS Disparities for Blacks in the United States: A Review of Antiretroviral and Mortality Studies. Journal of the National Medical Association, 2009, 101, 1221-1229.	0.6	11
106	HIV/AIDS Disparities: The Mounting Epidemic Plaguing US Blacks. Journal of the National Medical Association, 2009, 101, 1196-1204.	0.6	21
107	Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002. Clinical Therapeutics, 2008, 30, 2335-2341.	1.1	8
108	Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodynamic models with Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 2008, 61, 621-628.	1.3	94

#	Article	IF	CITATIONS
109	Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting. Oncologist, 2008, 13, 876-885.	1.9	62
110	Vaccination adherence and perceptions among infectious diseases pharmacists. American Journal of Health-System Pharmacy, 2008, 65, 1500-1501.	0.5	2
111	A Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU. Chest, 2008, 133, 610-617.	0.4	186
112	The contribution of pharmacokinetic–pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clinical Microbiology and Infection, 2007, 13, 33-39.	2.8	37
113	Dietary supplement use among anticoagulation clinic patients. Journal of Thrombosis and Haemostasis, 2007, 5, 875-877.	1.9	12
114	Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 447-451.	1.3	28
115	Impact of Guideline-Concordant Empiric Antibiotic Therapy in Community-Acquired Pneumonia. American Journal of Medicine, 2006, 119, 865-871.	0.6	124
116	Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: A data analysis. Clinical Therapeutics, 2006, 28, 1035-1040.	1.1	4
117	Continuous infusion \hat{l}^2 -lactams for intensive care unit pulmonary infections. Clinical Microbiology and Infection, 2005, 11, 418-421.	2.8	20
118	Pharmacodynamic Analysis of Ceftriaxone, Gatifloxacin,and Levofloxacin AgainstStreptococcus pneumoniaewith the Use of Monte Carlo Simulation. Pharmacotherapy, 2005, 25, 1161-1167.	1.2	21
119	Comparison of β-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. Journal of Antimicrobial Chemotherapy, 2005, 56, 893-898.	1.3	31
120	Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum β-lactamase-producing organisms. International Journal of Antimicrobial Agents, 2005, 26, 114-119.	1.1	33
121	Pharmacodynamic modeling of carbapenems andfluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clinical Therapeutics, 2004, 26, 1800-1807.	1.1	38
122	Community-Acquired Pneumonia:. Journal of Public Health Pharmacy, 2004, 6, 39-48.	0.1	2
123	Impact of Atypical Coverage for Patients with Community-Acquired Pneumonia Managed on the Medical Ward: Results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy, 2003, 23, 1167-1174.	1.2	23
124	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infection and Drug Resistance, 0, , 63.	1.1	4
125	Retrospective Cohort Evaluating the Comparative Effectiveness of Ceftaroline and Daptomycin as First-Line Therapies for Inpatient Treatment of Diabetic Foot Infection in the United States Veterans Health Care System. Drugs - Real World Outcomes, 0, , .	0.7	1